These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85. Cardiac electrophysiological modulation by NS-7, a novel neuroprotective drug, of guinea pig ventricular muscles. Satoh H Life Sci; 2003 Jan; 72(9):1039-48. PubMed ID: 12495782 [TBL] [Abstract][Full Text] [Related]
86. Developmental changes in IKr and IKs contribute to age-related expression of dofetilide effects on repolarization and proarrhythmia. Obreztchikova MN; Sosunov EA; Plotnikov A; Anyukhovsky EP; Gainullin RZ; Danilo P; Yeom ZH; Robinson RB; Rosen MR Cardiovasc Res; 2003 Aug; 59(2):339-50. PubMed ID: 12909317 [TBL] [Abstract][Full Text] [Related]
87. Azimilide decreases defibrillation voltage requirements and increases spatial organization during ventricular fibrillation. Qi XQ; Newman D; Dorian P J Interv Card Electrophysiol; 1999 Mar; 3(1):61-7. PubMed ID: 10354978 [TBL] [Abstract][Full Text] [Related]
88. Effects of azimilide, acidemia, and the combination on defibrillation energy requirements. Carnes CA; Mehdirad AA J Cardiovasc Pharmacol; 2000 Sep; 36(3):283-7. PubMed ID: 10975583 [TBL] [Abstract][Full Text] [Related]
89. Effects of azimilide, a new class III antiarrhythmic drug, on reentrant circuits causing ventricular tachycardia and fibrillation in a canine model of myocardial infarction. Schmitt H; Cabo C; Coromilas JC; Wit AL J Cardiovasc Electrophysiol; 2001 Sep; 12(9):1025-33. PubMed ID: 11573692 [TBL] [Abstract][Full Text] [Related]
90. Risperidone-induced action potential prolongation is attenuated by increased repolarization reserve due to concomitant block of I(Ca,L). Christ T; Wettwer E; Ravens U Naunyn Schmiedebergs Arch Pharmacol; 2005 May; 371(5):393-400. PubMed ID: 15959721 [TBL] [Abstract][Full Text] [Related]
91. Spinal cord stimulation reduces ventricular arrhythmias during acute ischemia by attenuation of regional myocardial excitability. Howard-Quijano K; Takamiya T; Dale EA; Kipke J; Kubo Y; Grogan T; Afyouni A; Shivkumar K; Mahajan A Am J Physiol Heart Circ Physiol; 2017 Aug; 313(2):H421-H431. PubMed ID: 28576833 [TBL] [Abstract][Full Text] [Related]
92. Protective effects of D,L-carnitine against arrhythmias induced by lysophosphatidylcholine or reperfusion. Duan J; Moffat MP Eur J Pharmacol; 1991 Jan; 192(3):355-63. PubMed ID: 2055235 [TBL] [Abstract][Full Text] [Related]
93. Effects of altered extracellular potassium and pacing cycle length on the class III antiarrhythmic actions of dofetilide (UK-68,798) in guinea-pig papillary muscle. Yang T; Tande PM; Lathrop DA; Refsum H Cardiovasc Drugs Ther; 1992 Aug; 6(4):429-36. PubMed ID: 1520650 [TBL] [Abstract][Full Text] [Related]
94. Efficacy of azimilide and dofetilide in the dog right atrial enlargement model of atrial flutter. Restivo M; Hegazy M; El-Hamami M; Yin H; Caref EB; Assadi MA; Brooks RR; El-Sherif N J Cardiovasc Electrophysiol; 2001 Sep; 12(9):1018-24. PubMed ID: 11573691 [TBL] [Abstract][Full Text] [Related]
95. Interaction of azimilide with neurohumoral and channel receptors. Brooks RR; Pong SF; Izzo NJ; Moorehead TJ; Gopalakrishnan M; Triggle DJ Biochem Pharmacol; 2001 Oct; 62(7):883-92. PubMed ID: 11543723 [TBL] [Abstract][Full Text] [Related]
97. Effect of channel modulation and pH on IsK inhibition by the novel class III antiarrhythmic azimilide (NE-10064). Herzer T; Wagner CA; Waldegger S; Lang F; Busch AE Eur J Pharmacol; 1995 Oct; 291(2):205-8. PubMed ID: 8566172 [TBL] [Abstract][Full Text] [Related]
98. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203 [TBL] [Abstract][Full Text] [Related]
99. Ischemic preconditioning: antiarrhythmic effects and electrophysiological mechanisms in isolated ventricle. Zhu J; Ferrier GR Am J Physiol; 1998 Jan; 274(1):H66-75. PubMed ID: 9458853 [TBL] [Abstract][Full Text] [Related]
100. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. Dorian P; Al-Khalidi HR; Hohnloser SH; Brum JM; Dunnmon PM; Pratt CM; Holroyde MJ; Kowey P; J Am Coll Cardiol; 2008 Sep; 52(13):1076-83. PubMed ID: 18848141 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]